Medicaid best price reforms to enable innovative payment models for cell and gene therapies

References

• Young CM, Quinn C, Trusheim MR. Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues. Drug Discov Today. 2022;27:17–30.
   PubMed Web of Science ®Google Scholar
• FDA. Transfer of therapeutic products to the Center for Drug Evaluation and Research (CDER) [Internet]. Transfer of therapeutic products to the Center for Drug Evaluation and Research (CDER). FDA; 2019 [cited 2022 Nov 21]. Available from: https://www.fda.gov/about-fda/center-biologics-evaluation-and-research-cber/transfer-therapeutic-products-center-drug-evaluation-and-research-cder
   Google Scholar
• FDA. Considerations for the development of Chimeric Antigen Receptor (CAR) T cell products [Internet]. FDA; 2022 cited 2022 Nov 1]. Available from 2022 Nov 1: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-development-chimeric-antigen-receptor-car-t-cell-products
   Google Scholar
• Tufts NEWDIGS. Precision financing solutions for durable/potentially curative therapies. [Internet]. Center for biomedical system design, institute for clinical research and health policy studies. Tufts Medical Center; 2019 [cited 2022 Nov 21]. Available from: https://newdigs.tuftsmedicalcenter.org/precision-financing-solutions-for-durable-potentially-curative-therapies/
   Google Scholar
• Barlow JF, Yang M, Teagarden JR. Are payers ready, willing, and able to provide access to new durable gene therapies? Value Health. 2019;22:642–647.
   PubMed Web of Science ®Google Scholar
• Barlow JF, Courtney MW, Trusheim M. Payer perspectives on gene therapy reimbursement. Pharm Exec. 2020;40(4):24–29. [Cited 2022 Dec 22]. https://www.pharmexec.com/view/payer-perspectives-gene-therapy-reimbursement
   Google Scholar
• Gottlieb S, Carino T. Establishing new payment provisions for the high cost of curing disease. AEI Res. 2014 July.
   Google Scholar
• Garrison LP, Jackson T, Paul D, et al. Value-based pricing for emerging gene therapies: the economic case for a higher cost-effectiveness threshold. J Manag Care Spec Pharm. 2019;25:793–799.
   PubMed Web of Science ®Google Scholar
• Cantrell, SA. AMCP partnership forum: advancing value-based contracting. J Manag Care Spec Pharm. 2017;23:1096–1102.
   PubMed Web of Science ®Google Scholar
• NEWDIGS T. Policy actions for enabling precision financing solutions [Internet]. Center for Biomedical System Design, Institute for Clinical Research and Health Policy Studies. Tufts Medical Center; 2021 [Cited 2022 Nov 21]. Available from: https://newdigs.tuftsmedicalcenter.org/wp-content/uploads/2021/02/P4C-Policy-Actions-201123.pdf
   Google Scholar
• Wenzl M, Chapman S Performance-based managed entry agreements for new medicines in OECD countries and EU member states: how they work and possible improvements going forward [Internet]. 2019 cited 2022 Mar 15]. Report No: 115. Available from 2022 Mar 15: https://www.oecd-ilibrary.org/social-issues-migration-health/performance-based-managed-entry-agreements-for-new-medicines-in-oecd-countries-and-eu-member-states_6e5e4c0f-en
   Google Scholar
• Neumann PJ, Chambers JD, Simon F, et al. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement. Health Aff (Millwood). 2011;30:2329–2337.
   PubMed Web of Science ®Google Scholar
• Ward AS, Linthicum MT, Drozd M, et al. Regulatory, legal uncertainties are barriers to value-based agreements for drugs
   Google Scholar
• Goodman C, Villarivera C, Gregor K, et al. Regulatory, policy, and operational considerations for outcomes-based risk-sharing agreements in the U.S. market: opportunities for reform. JMCP. 2019;25:1174–1181.
   PubMed Web of Science ®Google Scholar
• White J Medicaid “best price” approach to drug costs needs an upgrade [Internet]. STAT. 2017 cited 2022 Mar 15]. Available from 2022 Mar 15: https://www.statnews.com/2017/11/10/drug-pricing-medicaid-value-based/
   Google Scholar
• Garfield R, Dolan R, 2021. Costs and savings under federal policy approaches to address Medicaid prescription drug spending [internet]. KFF. cited 2022 Mar 15]. Available from 2022 Mar 15: https://www.kff.org/medicaid/issue-brief/costs-and-savings-under-federal-policy-approaches-to-address-medicaid-prescription-drug-spending/
   Google Scholar
• Glossary of common industry terms. [Internet]. Drug Pricing Lab. cited 2022 Mar 15]. Available from 2022 Mar 15: https://www.drugpricinglab.org/tools/glossary/
   Google Scholar
• Sachs R, Bagley N, Lakdawalla DN. Innovative contracting for pharmaceuticals and medicaid’s best-price rule. J Health Polit Policy Law. 2018;43:5–18.
   PubMed Web of Science ®Google Scholar
• Verma S. CMS’s proposed rule on value-based purchasing for prescription drugs: new tools for negotiating prices for the next generation of therapies. Health Affairs Blog. Internet]. 2020 June 17 [cited 2020 Nov 21]. Available from:. DOI:10.1377/hblog20200617.728496/full.
   Google Scholar
• Centers for Medicare & Medicaid Services. Medicaid program; establishing minimum standards in Medicaid state Drug Utilization Review (DUR) and supporting Value-Based Purchasing (VBP) for drugs covered in Medicaid, revising Medicaid drug rebate and Third Party Liability (TPL) requirements [Internet]. Centers for Medicare & Medicaid Services; 2020 cited 2020 Nov 21]. Available from 2020 Nov 21: https://www.federalregister.gov/documents/2020/06/19/2020-12970/medicaid-program-establishing-minimum-standards-in-medicaid-state-drug-utilization-review-dur-and
   Google Scholar
• van Overbeeke E, Michelsen S, Toumi M, et al. Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions. Drug Discov Today. 2021;26:399–415.
   PubMed Web of Science ®Google Scholar
• APEC. APEC Action Plan On Rare Diseases [Internet]. 2018 cited 2022 Mar 15. Available from: https://www.apec.org/docs/default-source/satellite/Rare-Diseases/APEC_ActionPlan.pdf
   Google Scholar
• FDA. Approved Cellular and Gene Therapy Products [Internet]. FDA. FDA; 2022 cited 2022 Nov 4. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
   Google Scholar
• Institute for clinical and economic review final report on CAR-T therapies highlights need for systemwide changes to ensure affordability and access to innovative, one-time therapies [internet]. ICER. cited 2020 Dec 31]. Available from 2020 Dec 31: https://icer.org/news-insights/press-releases/car-t-final-report/
   Google Scholar
• Dunleavy K In warranty program, Pfizer will refund up to $50K for patients who discontinue use of rare disease drug [Internet]. Fierce Pharma. 2022 cited 2022 Nov 4. Available from: https://www.fiercepharma.com/pharma/warranty-program-pfizer-will-refund-50k-patients-who-discontinue-use-rare-disease-drug
   Google Scholar
• Jørgensen J, Kefalas P. The use of innovative payment mechanisms for gene therapies in Europe and the USA. Regen Med. 2021;16:405–422.
   PubMed Web of Science ®Google Scholar
• Toolkit Home | NEWDIGS [Internet]. cited 2022 Nov 4]. Available from 2022 Nov 4: https://newdigs.tuftsmedicalcenter.org/toolkit/
   Google Scholar
• Trusheim MR, Cassidy WM, Bach PB. Alternative state-level financing for hepatitis c treatment—the “Netflix model. Jama. 2018;320:1977–1978.
   PubMed Web of Science ®Google Scholar
• Fingertip FormularyTM Suite [Internet]. Clarivate. cited 2022 Mar 15]. Available from 2022 Mar 15: https://clarivate.com/products/biopharma/market-access/fingertip-formulary/
   Google Scholar
• Dolan R, 2019. Understanding the Medicaid prescription drug rebate program [Internet]. KFF. cited 2022 Mar 15]. Available from 2022 Mar 15: https://www.kff.org/medicaid/issue-brief/understanding-the-medicaid-prescription-drug-rebate-program/
   Google Scholar
• Tully S The best way to lower drug prices: end the Medicaid program that blocks discounts [internet]. Fortune. cited 2022 Mar 15]. Available from 2022 Mar 15: https://fortune.com/2019/02/05/the-best-way-to-lower-drug-prices-end-the-medicaid-program-that-blocks-discounts/
   Google Scholar